Drug Profile
IMX 111
Alternative Names: Imx-111Latest Information Update: 05 Jan 2022
Price :
$50
*
At a glance
- Originator Immix Biopharma
- Class Antineoplastics
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 15 Dec 2021 Preclinical trials in Colorectal cancer in USA (unspecified route) (Immix Biopharma pipeline, January 2022)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 26 Sep 2016 Preclinical trials in Cancer in USA (unspecified route) (Immix Biopharma pipeline, September 2016)